First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

• Published in: Communications medicine Vol. 4; no. 1; p. 10
• Main Authors: Mahalingam, Devalingam, Harb, Wael, Patnaik, Amita, Bullock, Andrea, Watnick, Randolph S., Vincent, Melanie Y., Chen, Jian Jenny, Wang, Suming, Pestana, Harold, Chao, Judy, Mahoney, James, Cieslewicz, Michael, Watnick, Jing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 13.01.2024; Springer Nature B.V; Nature Portfolio
• Subjects: 631/67/1059/153; 692/4028/67/1059/153; 692/4028/67/1059/2325; Apoptosis; Biopsy; Bone marrow; Cancer therapies; Clinical outcomes; Disease control; Drug dosages; Mass spectrometry; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Ovarian cancer; Patients; Pharmacokinetics; Prostate; Scientific imaging; Toxicity; Tumors
• ISSN: 2730-664X; 2730-664X
• DOI: 10.1038/s43856-024-00433-x

Background VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding to CD36 and CD47 to induce tumor and endothelial cell apoptosis as well as immune modulation in the TME. Methods Study VT1021-01 (ClinicalTrials.gov ID NCT03364400) used a modified 3 + 3 design. The primary objective was to determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Safety, tolerability, and pharmacokinetics (PK) were assessed. Patients were dosed twice weekly intravenously in 9 cohorts (0.5–15.6 mg/kg). Safety was evaluated using CTCAE version 5.0 and the anti-tumor activity was evaluated by RECIST version 1.1. Results The RP2D of VT1021 is established at 11.8 mg/kg. VT1021 is well tolerated with no dose-limiting toxicities reported (0/38). The most frequent drug-related adverse events are fatigue (15.8%), nausea (10.5%), and infusion-related reactions (10.5%). Exposure increases proportionally from 0.5 to 8.8 mg/kg. The disease control rate (DCR) is 42.9% with 12 of 28 patients deriving clinical benefit including a partial response (PR) in one thymoma patient (504 days). Conclusions VT1021 is safe and well-tolerated across all doses tested. RP2D has been selected for future clinical studies. PR and SD with tumor shrinkage are observed in multiple patients underscoring the single-agent potential of VT1021. Expansion studies in GBM, pancreatic cancer and other solid tumors at the RP2D have been completed and results will be communicated in a separate report. Plain language summary It may be possible to treat cancers with therapies that modify the tumor microenvironment. This is the environment in the body in which tumors survive and grow and is composed of different types of cells. One such potential therapy is VT1021. Here, we conduct the first clinical trial to test this therapy in patients. We identify the optimal dose of the treatment to take into further studies, finding that VT1021 is safe and well tolerated by patients. We see some signs that the treatment is working in some patients and see evidence of modification of the tumor microenvironment. These findings help to inform further clinical trials of VT1021 to determine whether it is safe and effective in larger cohorts of patients. Mahalingam et al. report findings from a first-in-human dose escalation study of the tumor microenvironment modulator VT1021 in patients with advanced solid tumors. VT1021 is found to be safe and well tolerated and the recommended phase II dose is established based on pharmacokinetic/dynamic properties and preliminary clinical activities.